Clearpoint Neuro Inc (CLPT) - Net Assets
Based on the latest financial reports, Clearpoint Neuro Inc (CLPT) has net assets worth $28.02 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($97.75 Million) and total liabilities ($69.73 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Clearpoint Neuro Inc's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $28.02 Million |
| % of Total Assets | 28.67% |
| Annual Growth Rate | N/A |
| 5-Year Change | -42.57% |
| 10-Year Change | N/A |
| Growth Volatility | 648.63 |
Clearpoint Neuro Inc - Net Assets Trend (2011–2025)
This chart illustrates how Clearpoint Neuro Inc's net assets have evolved over time, based on quarterly financial data. Also explore Clearpoint Neuro Inc asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Clearpoint Neuro Inc (2011–2025)
The table below shows the annual net assets of Clearpoint Neuro Inc from 2011 to 2025. For live valuation and market cap data, see Clearpoint Neuro Inc (CLPT) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $28.02 Million | +10.36% |
| 2024-12-31 | $25.39 Million | +19.91% |
| 2023-12-31 | $21.17 Million | -42.60% |
| 2022-12-31 | $36.89 Million | -24.39% |
| 2021-12-31 | $48.79 Million | +1952.46% |
| 2020-12-31 | $2.38 Million | -48.17% |
| 2019-12-31 | $4.59 Million | +203.51% |
| 2018-12-31 | $1.51 Million | -74.08% |
| 2017-12-31 | $5.83 Million | +870.93% |
| 2016-12-31 | $-756.07K | +61.84% |
| 2015-12-31 | $-1.98 Million | -1874.62% |
| 2014-12-31 | $-100.33K | +98.53% |
| 2013-12-31 | $-6.83 Million | -19.12% |
| 2012-12-31 | $-5.74 Million | +73.74% |
| 2011-12-31 | $-21.84 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Clearpoint Neuro Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 15712139000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $294.00K | 1.05% |
| Other Comprehensive Income | $5.64 Million | 20.13% |
| Other Components | $239.00 Million | 852.94% |
| Total Equity | $28.02 Million | 100.00% |
Clearpoint Neuro Inc Competitors by Market Cap
The table below lists competitors of Clearpoint Neuro Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shenzhen Magic Design & Decoration Engineering Co Ltd
SHE:002856
|
$272.85 Million |
|
SPC Samlip Co Ltd
KO:005610
|
$272.99 Million |
|
ProKidney Corp.
NASDAQ:PROK
|
$273.18 Million |
|
Anavex Life Sciences Corp
NASDAQ:AVXL
|
$273.38 Million |
|
NeXGold Mining Corp
V:NEXG
|
$272.56 Million |
|
Hunan Copote Science Technology Co Ltd
SHG:600476
|
$272.46 Million |
|
Korea Information & Communications Co. Ltd
KQ:025770
|
$272.46 Million |
|
Cape Industries Ltd
KQ:064820
|
$272.33 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Clearpoint Neuro Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 25,389,000 to 28,020,000, a change of 2,631,000 (10.4%).
- Net loss of 25,540,000 reduced equity.
- New share issuances of 3,263,000 increased equity.
- Other comprehensive income increased equity by 5,641,000.
- Other factors increased equity by 19,267,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-25.54 Million | -91.15% |
| Share Issuances | $3.26 Million | +11.65% |
| Other Comprehensive Income | $5.64 Million | +20.13% |
| Other Changes | $19.27 Million | +68.76% |
| Total Change | $- | 10.36% |
Book Value vs Market Value Analysis
This analysis compares Clearpoint Neuro Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 11.49x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $-54.47 | $11.37 | x |
| 2012-12-31 | $-5.68 | $11.37 | x |
| 2013-12-31 | $-4.77 | $11.37 | x |
| 2014-12-31 | $-0.07 | $11.37 | x |
| 2015-12-31 | $-1.05 | $11.37 | x |
| 2016-12-31 | $-0.27 | $11.37 | x |
| 2017-12-31 | $0.75 | $11.37 | x |
| 2018-12-31 | $0.14 | $11.37 | x |
| 2019-12-31 | $0.35 | $11.37 | x |
| 2020-12-31 | $0.15 | $11.37 | x |
| 2021-12-31 | $2.35 | $11.37 | x |
| 2022-12-31 | $1.53 | $11.37 | x |
| 2023-12-31 | $0.86 | $11.37 | x |
| 2024-12-31 | $0.94 | $11.37 | x |
| 2025-12-31 | $0.99 | $11.37 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Clearpoint Neuro Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -91.15%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -69.08%
- • Asset Turnover: 0.38x
- • Equity Multiplier: 3.49x
- Recent ROE (-91.15%) is below the historical average (-85.40%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 0.00% | -217.68% | 1.26x | 0.00x | $-6.13 Million |
| 2012 | 0.00% | -112.83% | 0.91x | 0.00x | $-5.13 Million |
| 2013 | 0.00% | -180.29% | 0.50x | 0.00x | $-6.40 Million |
| 2014 | 0.00% | -125.53% | 0.27x | 0.00x | $-4.51 Million |
| 2015 | 0.00% | -183.91% | 0.45x | 0.00x | $-8.25 Million |
| 2016 | 0.00% | -140.36% | 0.78x | 0.00x | $-7.99 Million |
| 2017 | -122.97% | -97.12% | 0.53x | 2.38x | $-7.75 Million |
| 2018 | -407.91% | -83.82% | 0.94x | 5.20x | $-6.31 Million |
| 2019 | -120.80% | -49.39% | 0.94x | 2.60x | $-6.00 Million |
| 2020 | -285.32% | -52.86% | 0.43x | 12.42x | $-7.02 Million |
| 2021 | -29.54% | -88.41% | 0.25x | 1.34x | $-19.29 Million |
| 2022 | -44.55% | -79.97% | 0.37x | 1.50x | $-20.12 Million |
| 2023 | -104.33% | -92.21% | 0.56x | 2.01x | $-24.21 Million |
| 2024 | -74.50% | -60.25% | 0.80x | 1.54x | $-21.45 Million |
| 2025 | -91.15% | -69.08% | 0.38x | 3.49x | $-28.34 Million |
Industry Comparison
This section compares Clearpoint Neuro Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,432,799,891
- Average return on equity (ROE) among peers: -74.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Clearpoint Neuro Inc (CLPT) | $28.02 Million | 0.00% | 2.49x | $272.79 Million |
| Abbott Laboratories (ABT) | $24.16 Billion | 9.46% | 0.81x | $155.56 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-13.54K | 0.00% | 0.00x | $21.60 Million |
| Aethlon Medical Inc (AEMD) | $9.29 Million | -84.45% | 0.15x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $105.73 Million | -116.68% | 0.61x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $1.39 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $2.15 Million | -112.84% | 0.45x | $16.04 Million |
| Allurion Technologies, Inc. (ALUR) | $-70.49 Million | 0.00% | 0.00x | $8.60 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $644.00K | -309.01% | 0.34x | $4.22 Million |
| Artivion Inc (AORT) | $89.39 Million | 8.74% | 0.25x | $1.73 Billion |
| Apyx Medical Inc (APYX) | $21.15 Million | 2.82% | 0.30x | $125.55 Million |
About Clearpoint Neuro Inc
ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which … Read more